Certolizumab pegol for the treatment of Crohn’s disease

References

• Caprilli R, Angelucci E, Clemente V. Recent advances in the management of Crohn’s disease. Dig. Liver Dis.40, 709–716 (2008).
   PubMedGoogle Scholar
• Fleischmann R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res. Ther.6(Suppl. 2), S12–S18 (2004).
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Porro GB. Biologic therapy for inflammatory bowel disease. Drugs65, 2253–2286 (2005).
   PubMed Web of Science ®Google Scholar
• Papachristou GI, Plevy S. Novel biologics in inflammatory bowel disease. Gastroenterol. Clin. N. Am.33, 251–269 (2004).
   PubMed Web of Science ®Google Scholar
• Ruiz Garcia V, Burls A, Cabello Lopez JCL et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst. Rev.1, CD007649 (2009).
   Google Scholar
• Cimzia®, package insert. UCB, Inc., Smyrna, GA, USA (May 2009).
   Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology129, 807–818 (2005).
   PubMed Web of Science ®Google Scholar
• Lim WC, Hanauer SB. Emerging biologic therapies in inflammatory bowel disease. Rev. Gastroenterol. Disord.4(2), 66–85 (2004).
   PubMedGoogle Scholar
• Gramlick A, Henry A, Fossati G, Nesbitt A. Neutralization of soluble and membrane TNFa by infliximab, adalimumab, and certolizumab pegol using a p55 TNF receptor-specific bioassay. Presented at: Digestive Disease Week. American Gastroenterological Association, Los Angeles, CA, USA, 20–25 May 2006.
   Google Scholar
• Nesbitt AM, Gramlick A, Fossati G. Neutralization of soluble and membrane tumor necrosis factor-α (TNF-α) by infliximab, adalimumab, or certolizumab pegol using p55 or p75 TNF-α receptor-specific bioassays [abstract]. Presented at: Digestive Disease Week. American Gastroenterological Association, Los Angeles, CA, USA, 20–25 May 2006.
   Google Scholar
• Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor a agents. Inflamm. Bowel Dis.13, 1323–1332 (2007).
   PubMed Web of Science ®Google Scholar
• Baker M, Stephens S. Investigation of the pharmacokinetics properties of certolizumab pegol, an anti-TNF agent [abstract]. Presented at: 2006 American College of Gastroenterology Annual Scientific Meeting. Las Vegas, NV, USA, 20–25 October 2006 (Abstract 750808).
   Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance I et al. Certolizumab pegol, a humanised anti-TNF pegylated Fab’ fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a Phase III study (Precise). Gut54(Suppl. VII), A82 (2005).
   Web of Science ®Google Scholar
• Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab’ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn’s disease: an exploratory study. Aliment. Pharmacol. Ther.20, 1337–1346 (2004).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26-week, placebo-controlled Phase III study (PRECiSE 1) [abstract]. Presented at: Digestive Disease Week. American Gastroenterological Association, Los Angeles, CA, USA, 20–25 May 2006 (Abstract 745).
   Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med.357, 228–238 (2007).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Feagan B, Hanauer SB, Rutgeerts P, McColm JA, Sandborn WJ. Safety and tolerability of subcutaneous (sc) certolizumab pegol in active Crohn’s disease (CD): results from two Phase III studies (PRECiSE program) [abstract]. Presented at: Digestive Disease Week. American Gastroenterological Association, Los Angeles, CA, USA, 20–25 May 2006 (Abstract T1126).
   Google Scholar
• Schreiber S, Lawrance IC, McColm JA, Bloomfield R, Sandborn WJ. How effective is anti-TNF-α therapy? A re-analysis of the PRECiSE 2 maintenance trial of monthly subcutaneous certolizumab pegol in active Crohn’s disease using remission to redefine all efficacy measures (abstract). Presented at: Digestive Disease Week. American Gastroenterological Association, Los Angeles, CA, USA, 20–25 May 2006 (Abstract T1140).
   Google Scholar
• UCB submits Biologics License Application to FDA for new treatment in Crohn’s disease [press release]. UCB, Brussels, Belgium and Atlanta, GA, USA. 2 March 2006.
   Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med.357, 239–250 (2007).
   PubMed Web of Science ®Google Scholar
• Impact of Crohn’s disease and treatment with Certolizumab pegol 400 mg every 4 weeks on patient-reported health status: Data from PRECiSE 2. Presented at: The American College of Gastroenterology Annual Scientific Meeting. Las Vegas, NV, USA, 20–25 October 2006 (Abstract 751277).
   Google Scholar
• Brown M, Thomsen OO, Purcaru O, Schreiber S. PRECISE2 data demonstrate a high association between work productivity, daily activities and clinical endpoints in Crohn’s disease. Presented at: The American College of Gastroenterology Annual Scientific Meeting. Las Vegas, NV, USA, 20–25 October 2006 (Abstract 750810).
   Google Scholar
• Feagan B, Coteur G, Keininger D. Certolizumab pegol relieves the symptoms of Crohn’s disease, including those rated as the most severe [abstract]. Inflamm. Bowel Dis.14(Suppl.), S13 (2008).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Panes J, Mason D, Lichtensetin G, Sandborn W. Efficacy and tolerability of certolizumab pegol are sustained over 18 months: data from PRECISE 2 and its extension studies (PRECISE 3 and 4) [abstract]. Inflamm. Bowel Dis.14(Suppl.), S8 (2008).
   Google Scholar
• Lichtenstein GR, Mitchev K, D’Haens G. RE-induction with certolizumab pegol following disease exacerbation during maintenance therapy is effective to regain response and remission [abstract]. Presented at: Digestive Disease Week. San Diego, CA, USA, 17–22 May 2008 (Abstract T1120).
   Google Scholar
• Danese S, Mocciaro F, Guidi L et al. Successful induction of clinical response and remission with certolizumab pegol in Crohn’s disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use [letter]. Inflamm. Bowel Dis.14(8), 1168–1170 (2008).
   PubMed Web of Science ®Google Scholar
• Feagan B, Tan S, Brown M. Impact of certolizumab pegol on quality-adjusted life-years in two induction and maintenance trials in patients with active Crohn’s disease [abstract]. Presented at: Digestive Disease Week. San Diego, CA, USA, 17–22 May 2008 (Abstract 943).
   Google Scholar
• Coteur G, Feagan B, Keininger DL, Kosinski M. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn’s disease. Aliment. Pharmacol. Ther.29, 1032–1041 (2009).
   PubMed Web of Science ®Google Scholar
• D’Haens G, Mitchev K, Sandborn WJ. Response and remission at 18 months of certolizumab pegol in patients with active Crohn’s disease is not influenced by rapidity and magnitude of induction: an analysis of PRECiSE 2 and 3 [abstract]. Presented at: Digestive Disease Week. San Diego, CA, USA, 17–22 May 2008 (Abstract T1126).
   Google Scholar
• Hommes DW. Response to certolizumab pegol induction is not steroid-dependent in patients with active Crohn’s disease [abstract]. Presented at: Digestive Disease Week. San Diego, CA, USA, 17–22 May 2008 (Abstract T1149).
   Google Scholar
• Vermeire S, Collin B, Mitchev K, Howaldt S, Hommes D, Rutgeerts P. Certolizumab pegol in patients with Crohn’s disease who failed treatment with other anti-TNFs: data from a compassionate use program [abstract]. Inflamm. Bowel Dis.14(Suppl.), S29 (2008).
   PubMed Web of Science ®Google Scholar
• Vermeire S, Abreu MT, D’Haens G et al. Efficacy and safety of certolizumab pegol in patients with active Crohn’s disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the Welcome Study [abstract]. Presented at: Digestive Disease Week. San Diego, CA, USA, 17–22 May 2008 (Abstract 494).
   Google Scholar
• Vermeire S, Abreu M, D’Haens G et al. Efficacy and safety of certolizumab pegol in patients with active Crohn’s disease who previously lost response or were intolerant to infliximab: open-label induction results of the WELCOME Study [abstract]. Inflamm. Bowel Dis.14(12 Suppl. 3), S30 (2008).
   Google Scholar
• Hanauer SB, Schreiber S, Thomsen OO, Lichtenstein GR, Bloomfield R, Sandborn WJ. Predictors of response in patients with active Crohn’s disease treated with certolizumab pegol: a multiple regression analysis of Precise 2 data [abstract]. Presented at: Digestive Disease Week. San Diego, CA, USA, 17–22 May 2008 (Abstract T1129).
   Google Scholar
• Sandborn W, Lichtenstein G, Schreiber S, Feagan B. The long-term, 30-month, efficacy and tolerability of certolizumab pegol therapy for Crohn’s disease. [abstract]. Inflamm. Bowel Dis.14(12 Suppl. 3), S29 (2008).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Lawranc I, Thomsen O, Hanauer S, Bloomfield R, Sandborn W. CIMZIA (certolizumab pegol) is effective in the treatment of Crohn’s disease patients with open fistulas [abstract]. Inflamm. Bowel Dis.14(12 Suppl. 3), S1 (2008).
   PubMed Web of Science ®Google Scholar
• Colombel J, Lemann M, Bouhnik Y et al. Endoscopic mucosal improvement in patients with active Crohn’s disease treated with certolizumab pegol: first results of the MUSIC clinical trial [abstract]. Inflamm. Bowel Dis.14(12 Suppl. 3), S25 (2008).
   Google Scholar
• Colombel J, Schreiber S, Rutgeerts P, Sandborn W, Hanauer S. Long-term safety of certolizumab pegol in Crohn’s disease: integrated safety findings on serious adverse events of special interest [abstract]. Inflamm. Bowel Dis.14(12 Suppl. 3), S16 (2008).
   Google Scholar
• Nesbitt AM, Stephens S, Bloomfield R. Neutralising antibodies to certolizumab pegol do not appear to impact on efficacy or safety in patients with Crohn’s disease [abstract]. Gut57(Suppl. 1), A142 (2008).
   Google Scholar
• Schwartzman S, Fleischmann R, Morgan GJ. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res. Ther.6(Suppl. 2), S3–S11 (2004).
   Google Scholar
• Remicade®, package insert. Centocor, Inc., Malvern, PA, USA (April 2007).
   Google Scholar
• Humira®, package insert. Abbott Laboratories, North Chicago, IL, USA (February 2008).
   Google Scholar
• Behm BW, Bickston SJ. Tumor necrosis factor-α antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev.1, CD006893 (2008).
   Google Scholar
• Cimzia®, package insert. UCB Inc., Smyrna, GA, USA (April 2008).
   Google Scholar